Systematic analysis of funding awarded for antimicrobial resistance research to institutions in the UK, 19972010

被引:17
作者
Head, Michael G. [1 ]
Fitchett, Joseph R. [2 ]
Cooke, Mary K. [1 ]
Wurie, Fatima B. [1 ]
Atun, Rifat [3 ,4 ,5 ]
Hayward, Andrew C. [1 ]
Holmes, Alison [6 ]
Johnson, Alan P. [7 ]
Woodford, Neil [8 ]
机构
[1] UCL, Res Dept Infect & Populat Hlth, London NW3 2PF, England
[2] London Sch Hyg & Trop Med, London WC1, England
[3] Univ London Imperial Coll Sci Technol & Med, Imperial Coll Business Sch, London, England
[4] Univ London Imperial Coll Sci Technol & Med, Fac Med, London, England
[5] Harvard Univ, Harvard Sch Publ Hlth, Boston, MA 02115 USA
[6] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Ctr Infect Prevent & Management, London W12 0HS, England
[7] Publ Hlth England, Dept Healthcare Associated Infect & Antimicrobial, London NW9 5EQ, England
[8] Publ Hlth England, Antimicrobial Resistance & Healthcare Associated, London NW9 5EQ, England
基金
英国医学研究理事会; 比尔及梅琳达.盖茨基金会; 英国生物技术与生命科学研究理事会; 英国惠康基金;
关键词
antibiotics; antifungal; antiviral; antiparasitic; DRUG; MULTIRESISTANT; SURVEILLANCE; PATHOGENS; DISEASE; SPREAD;
D O I
10.1093/jac/dkt349
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To assess the level of research funding awarded to UK institutions specifically for antimicrobial resistance-related research and how closely the topics funded relate to the clinical and public health burden of resistance. Databases and web sites were systematically searched for information on how infectious disease research studies were funded for the period 19972010. Studies specifically related to antimicrobial resistance, including bacteriology, virology, mycology and parasitology research, were identified and categorized in terms of funding by pathogenand disease and by a research and development value chain describing the type of science. The overall dataset included 6165 studies receiving a total investment of 2.6 billion, of which 102 million was directed towards antimicrobial resistance research (5.5 of total studies, 3.9 of total spend). Of 337 resistance-related projects, 175 studies focused on bacteriology (40.2 of total resistance-related spending), 42 focused on antiviral resistance (17.2 of funding) and 51 focused on parasitology (27.4 of funding). Mean annual funding ranged from 1.9 million in 1997 to 22.1 million in 2009. Despite the fact that the emergence of antimicrobial resistance threatens our future ability to treat many infections, the proportion of the UK infection-research spend targeting this important area is small. There are encouraging signs of increased investment in this area, but it is important that this is sustained and targeted at areas of projected greatest burden. Two areas of particular concern requiring more investment are tuberculosis and multidrug-resistant Gram-negative bacteria.
引用
收藏
页码:548 / 554
页数:7
相关论文
共 32 条
[1]   Tuberculosis 2013:5 Drug-resistant tuberculosis: time for visionary political leadership [J].
Abubakar, Ibrahim ;
Zignol, Matteo ;
Falzon, Dennis ;
Raviglione, Mario ;
Ditiu, Lucica ;
Masham, Susan ;
Adetifa, Lfedayo ;
Ford, Nathan ;
Cox, Helen ;
Lawn, Stephen D. ;
Marais, Ben J. ;
McHugh, Timothy D. ;
Mwaba, Peter ;
Bates, Matthew ;
Lipman, Marc ;
Zijenah, Lynn ;
Logan, Simon ;
McNerney, Ruth ;
Zumla, Adam ;
Sarda, Krishna ;
Nahid, Payam ;
Hoelscher, Michael ;
Pletschette, Michel ;
Memish, Ziad A. ;
Kim, Peter ;
Hafner, Richard ;
Cole, Stewart ;
Migliori, Giovanni Battista ;
Maeurer, Markus ;
Schito, Marco ;
Zumla, Alimuddin .
LANCET INFECTIOUS DISEASES, 2013, 13 (06) :529-539
[2]  
[Anonymous], 2012, FUNDING NEW RES ANTI
[3]  
Antibiotic Action, 2013, ARMS RAC
[4]   Tuberculosis 7 Health-system strengthening and tuberculosis control [J].
Atun, Rifat ;
Weil, Diana E. C. ;
Eang, Mao Tan ;
Mwakyusa, David .
LANCET, 2010, 375 (9732) :2169-2178
[5]   Prevalence of extended spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa:: regional results from SENTRY Antimicrobial Surveillance Program (1998-99) [J].
Bell, JM ;
Turnidge, JD ;
Gales, AC ;
Pfaller, MA ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 42 (03) :193-198
[6]  
Chaudhuri B N, 2011, J Assoc Physicians India, V59, P287
[7]   Health-care system frailties and public health control of communicable disease on the European Union's new eastern border [J].
Coker, RJ ;
Atun, RA ;
McKee, M .
LANCET, 2004, 363 (9418) :1389-1392
[8]   Appropriate vs. inappropriate antimicrobial therapy [J].
Davey, P. G. ;
Marwick, C. .
CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 :15-21
[9]   Annual Report of the Chief Medical Officer: infection and the rise of antimicrobial resistance [J].
Davies, Sally C. ;
Fowler, Tom ;
Watson, John ;
Livermore, David M. ;
Walker, David .
LANCET, 2013, 381 (9878) :1606-1609
[10]  
Department of Health, 2013, CHIEF MED OFF ANN RE, V2